Business Wire

Temenos Revolutionises its Banking Software, with the Launch of Two New Cloud-Native, Cloud-Agnostic Products – Temenos Infinity & Temenos T24 Transact to Accelerate Cloud Adoption

Share

Temenos (SIX: TEMN) the banking software company, today marked a major milestone with the launch of two new products. Temenos Infinity – a breakthrough digital front office product and Temenos T24 Transact – the next generation in core banking. These new products combine the most complete banking functionality in the market, leveraging 25 years of functionality from 3,000 banks in over 150 countries with the most advanced cloud-native, cloud-agnostic, API first technology and design-led thinking.

Through APIs, both products can be implemented independently or integrated. Clients will be able to roll-out new applications in hours utilising advanced continuous deployment tools and methodologies.

The conversion from Temenos’ existing Digital Front Office and T24 Core Banking products are automatic and upgrades for existing clients to the new cloud-native, cloud-agnostic Temenos products are available from April 2019. All Temenos SaaS products run on the new Temenos platform.

Temenos Infinity is the major next step in the award winning Temenos Digital Front Office product, which has over 300 banking clients. Temenos Infinity is an independent, omni-channel digital banking product which helps banks transform multiple siloed banking channels and legacy applications into a fast, consistent, frictionless customer journey. Through design-led thinking, user journeys and multi-country onboarding capabilities, Temenos Infinity enables banks to orchestrate all their customers’ touchpoints and interactions.

With its open API-first design, Temenos Infinity enables banks to connect with a wider ecosystem of financial and non-financial providers as well as the developer community to innovate and bring products to market faster. Temenos Infinity also integrates the recently purchased Avoka platform, the leading product in digital customer acquisition and onboarding. Temenos Infinity can be easily implemented through APIs as an independent front office platform on a third-party core banking system or integrated with the market-leading Temenos T24 Transact product.

Temenos T24 Transact is the most complete core banking product leveraging the most advanced cloud-native banking technology. Temenos T24 Transact takes the deep and extensive banking capabilities of Temenos T24 Core Banking, the world’s #1 core banking product supporting over 700 banks across all banking segments and re-platforms them onto a new, cloud-native and cloud-agnostic platform. The isolation of the banking functionality from the technology platform has been a hallmark of Temenos products and has allowed Temenos for the past 25 years to remain the most technologically advanced and functionally rich product in the world.

Temenos Infinity and Temenos T24 Transact can be deployed on-premise, in a customer cloud or managed by Temenos Cloud. All products run on Microsoft Azure, AWS and the Google Cloud platform.

David Arnott, Chief Executive Officer, Temenos, said: “We have been at the forefront of innovation for the last 25 years, investing over 20% of our revenues in R&D and we were the first to launch a core banking system in the cloud in 2011. This marks another key milestone as we revolutionise our banking software to accelerate cloud adoption. We see the market opportunity for packaged software expand significantly as banks look for a faster time to value.

The launch of Temenos Infinity and Temenos T24 Transact gives clients the most complete set of digital front office and core banking capabilities. Using the latest cloud-native, cloud-agnostic technology, banks are able to rapidly and elastically scale benefiting from the highest levels of security and multi-cloud resilience, generating up to 10x in infrastructure savings. Advanced API-first technology coupled with leading design-led thinking and continuous deployment empower banks to rapidly innovate, connecting to ecosystems and enabling developers to build in the morning and consume in the afternoon. These substantial benefits apply equally to banks whether they are running their software on-premise, on private or public clouds.”

Both Temenos Infinity and Temenos T24 Transact leverage the common Temenos Platform architecture. Key features and benefits include:

Continuous deployment - With advanced and automated tools and methodology, the testing and deployment of change means banks can reduce their release cycles from months to hours enabling them to roll-out new applications at speed.

Open APIs - Banking applications of the future will integrate and form part of a wider ecosystem. The enhanced Temenos Developers portal has an extensive library of published APIs for clients, partners and any third party development teams empowering them to innovate at speed and accelerating time to value. In addition, clients can connect to the Temenos’ MarketPlace, an online digital store, which brings together over 150 financial software products from over 65 certified fintech partners that are fully pre-integrated into the Temenos software.

Cloud-native, Cloud-agnostic - Banks now have an infrastructure to support the flexible experiences demanded by today’s digital customers. Elastic scalability eliminates the need to over-provision costly infrastructure and enables banks to pay for their actual usage, yielding significant costs savings. Hyperscaling means banks can respond to any surge in demand by scaling their applications up and down automatically. Temenos’ cloud-agnostic approach enables the highest levels of long-term resilience and redundancy without creating a dependency to a single technology provider. This is a key Temenos strategy and an answer to regulatory concerns.

Distributed databases - Traditional relational databases are not always fit to gain the maximum benefits from the cloud. The Temenos products support distributed databases that are natively designed and optimised for the cloud. Through a strategic partnership and participation in NuoDB an enterprise-class distributed SQL database provider, banks will benefit from unlimited processing capacity, auto-elastic scalability and the highest levels of active/active resilience across data centers, geographies and cloud platforms.

Temenos Infinity and Temenos T24 Transact will be showcased at the Temenos Community Forum (TCF), 2-4 April 2019, The Hague, The Netherlands.

About Temenos

Temenos AG (SIX: TEMN), headquartered in Geneva, is the world’s leader in banking software, partnering with banks and other financial institutions to transform their businesses and stay ahead of a changing marketplace. Over 3,000 firms across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic front office and corebanking, payments, fund management and wealth management software products enabling banks to deliver both consistent, frictionless customer journeys and gain operational excellence. Temenos customers are proven to be more profitable than their peers: over a seven-year period, they enjoyed on average a 31% higher return on assets, a 36% higher return on equity and an 8.6 percentage point lower cost/income ratio than banks running legacy applications. For more information please visit www.temenos.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors
Adam Snyder
Head of Investor Relations, Temenos
Email: asnyder@temenos.com
Tel: +41 22 708 1515

Media
Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: UKNewgateTemenos@newgatecomms.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

HiddenA line styled icon from Orion Icon Library.Eye